NCT04537156 2025-11-21
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
Xiamen University
Phase 3 Active not recruiting
Clinical Trials
22 trialsNCT02834637 2025-09-10
DoRIS
London School of Hygiene and Tropical Medicine
Phase 3 Active not recruiting
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT01263327 2020-07-10
Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
Xiamen University
Phase 1 Completed
NCT01381575 2020-06-09
Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls
GlaxoSmithKline
Phase 3 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00637195 2020-01-03
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
GlaxoSmithKline
Phase 3 Completed
NCT00294047 2020-01-02
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
GlaxoSmithKline
Phase 3 Completed
NCT00423046 2020-01-02
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00534638 2019-11-15
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
GlaxoSmithKline
Phase 4 Completed
NCT01190176 2019-10-30
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
GlaxoSmithKline
Phase 3 Completed
NCT02837926 2019-04-10
CoheaHr-WP4
CHU de Reims
Phase 4 Completed
NCT00128661 2019-03-08
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
GlaxoSmithKline
Phase 3 Completed
NCT00492544 2018-09-04
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed
NCT00578227 2018-08-17
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00485732 2018-07-20
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
GlaxoSmithKline
Phase 3 Completed
NCT00549900 2018-07-20
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
GlaxoSmithKline
Phase 1 Completed
NCT00799825 2018-07-12
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
GlaxoSmithKline
Phase 3 Completed
NCT00546078 2018-06-26
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
GlaxoSmithKline
Phase 2 Completed
NCT02276521 2015-09-23
Evaluation of Long Term Immunity Following HPV Vaccination
Murdoch Childrens Research Institute
Completed
NCT02296255 2014-11-20
Effect of HPV Vaccination on Women Aged 25 Years
Cancer Prevention and Research Institute, Italy
Phase 4 Completed